Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24696823 | 1.00 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1ECE1TDP1 | |
| SCHEMBL3042873 | 1.00 | SLC1A3 (0.43) | SLC1A3SLC1A2SLC1A1ECE1TDP1 | |
| SCHEMBL17066710 | 0.82 | ECE1 (0.37) | SLC1A3SLC1A2SLC1A1ECE1TDP1 | |
| SCHEMBL2450288 | 0.80 | ECE1 (0.44) | SLC1A3SLC1A2SLC1A1ECE1TDP1 | |
| SCHEMBL22952375 | 0.80 | SLC1A3 (0.42) | SLC1A3SLC1A2SLC1A1ECE1TDP1 | |
| SCHEMBL2450285 | 0.80 | ECE1 (0.44) | SLC1A3SLC1A2SLC1A1ECE1TDP1 | |
| SCHEMBL24696825 | 0.80 | ECE1 (0.44) | SLC1A3SLC1A2SLC1A1ECE1TDP1 | |
| SCHEMBL3042939 | 0.78 | SMN1; SMN2 (0.40) | ECE1MAPTMCL1LMNA | |
| SCHEMBL3042933 | 0.78 | SMN1; SMN2 (0.40) | ECE1MAPTMCL1LMNA | |
| SCHEMBL3217572 | 0.78 | TDP1 (0.50) | SLC1A3SLC1A2SLC1A1ECE1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-08-12 | — | — | US | disclosed |
| EP-2066688-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | Novartis AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008033389-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204159-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | SLC1A3 1467/4885SLC1A2 1427/4885SLC1A1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.